Case Reports in Oncological Medicine最新文献

{"title":"Dermatofibrosarcoma Protuberans of the Forehead: Case Report of a Rare Entity and Review of Literature.","authors":"Ulrich Igor Mbessoh Kengne, Jaafar Ibn Abou Talib Thiam, Amacoumba Fall, Salif Balde, Mamadou Ndiaye, Joel Gabin Konlack Mekontso, Gorgui Sarr, Etienne Tossou Zoure, Mamadou Sow, Sidy Ka","doi":"10.1155/crom/9991548","DOIUrl":"https://doi.org/10.1155/crom/9991548","url":null,"abstract":"<p><p>Dermatofibrosarcoma protuberans (DFSP) is a rare soft tissue sarcoma originating from fibroblasts in the dermal connective tissue, comprising approximately 1% of all soft tissue sarcomas. While most cases involve the trunk and extremities, only 10%-15% occur in the cephalic region, representing less than 1% of all head and neck neoplasms. DFSP is notable for its high propensity for local recurrence following surgical excision and its low metastatic potential. We report a case of recurrent DFSP of the forehead extending to the anterior wall of the left frontal sinus, without brain involvement, in a 33-year-old male with a history of three prior wide local excisions. A multidisciplinary cancer team recommended systemic imatinib therapy. This case highlights the challenges of managing DFSP in an uncommon location, underscoring the importance of a multidisciplinary approach in addressing recurrent and complex presentations.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2025 ","pages":"9991548"},"PeriodicalIF":0.6,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12081156/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insidious Primary Mediastinal Large B-Cell Lymphoma in a Young Female: A Case Report and Literature Review.","authors":"Neil Gambhir, Paul Youn, Moein Bayat Mokhtari, Patricia Lin Kwan, Thida Aye, Wan Ling Lam","doi":"10.1155/crom/9983831","DOIUrl":"https://doi.org/10.1155/crom/9983831","url":null,"abstract":"<p><p>Primary mediastinal large B-cell lymphoma (PMBCL) is a highly aggressive malignancy primarily observed in female patients during their third decade of life. This rare condition, with an incidence of 0.4 per million, traditionally presents with B symptoms or compressive-based sequela such as SVC syndrome or respiratory distress. In this report, we present the case of a young female who presented for palpitations and tachycardia without cardiopulmonary compressive-based symptoms diagnosed with a large 16-cm infiltrative PMBCL localized in the left ventricle.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2025 ","pages":"9983831"},"PeriodicalIF":0.6,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12049244/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144062463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful Treatment of Innumerable Untreated Brain Metastases With Trastuzumab Deruxtecan in Chemotherapy-Naïve HER2-Mutated Non-Small-Cell Lung Cancer.","authors":"Sara Young, Sean C Dougherty, Angela M DeRidder, Camilo E Fadul, Ryan D Gentzler","doi":"10.1155/crom/9936011","DOIUrl":"https://doi.org/10.1155/crom/9936011","url":null,"abstract":"<p><p>In non-small-cell lung cancer (NSCLC), activating human epidermal growth factor receptor 2 (HER2) mutations are found in a small subset of patients and are associated with a higher incidence of brain metastases (BMETSs), conferring poor survival outcomes. Trastuzumab deruxtecan (T-DXd) was recently approved as a second-line agent for use in patients with previously treated, unresectable, or metastatic HER2-mutated NSCLC. We present a case of HER2-mutated NSCLC with BMETS, treated with T-DXd to defer whole-brain radiotherapy (WBRT) because of the concern of long-term neurotoxicity. He initially also received bevacizumab to address the cerebral edema, which allowed stopping corticosteroids. After the first two doses, the patient had remarkable clinical and imaging (brain and systemic) responses without progression after more than 1 year of treatment. T-DXd may be an effective and durable therapy for patients with HER2-mutated NSCLC with brain metastases in situations where intracranial disease would otherwise warrant WBRT. Clinical trials are needed to understand the efficacy and durability of T-DXd in NSCLC with BMETS and the optimal sequence of available therapies.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2025 ","pages":"9936011"},"PeriodicalIF":0.6,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12043382/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143968209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sustained Remission With Atezolizumab in a Frail, Geriatric Patient With Advanced-Stage Large Cell Neuroendocrine Carcinoma Lung.","authors":"Mayank Kapoor, Praneet Bedi, Deepak Sundriyal, Ashita Jain, Ujjawal Shriwastav, Amit Sehrawat","doi":"10.1155/crom/2406678","DOIUrl":"10.1155/crom/2406678","url":null,"abstract":"<p><p>Large cell neuroendocrine carcinoma (LCNEC) is a rare, aggressive cancer primarily found in the lungs but can also occur in other organs. It is characterized by rapid progression and high metastatic potential. We present a case of advanced-stage LCNEC lung in a patient with a poor performance status (PS), requiring oxygen support. Imaging revealed a large right upper lobe mass, lymphadenopathy, with bronchial encasement and invasion into the superior vena cava, leading to SVC syndrome and pleural effusion. Biopsy and immunohistochemistry confirmed LCNEC. Due to the patient's poor PS, treatment began with low-dose single-agent chemotherapy (carboplatin), followed by etoposide and cisplatin after improvement. Local radiation was also administered, and the treatment plan was adjusted to include atezolizumab. After 10 cycles, the patient achieved complete remission, sustained for 6 years. This case highlights the complexities of managing advanced LCNEC in a geriatric patient and the effectiveness of a multidisciplinary approach and immunotherapy.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2025 ","pages":"2406678"},"PeriodicalIF":0.6,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11976032/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cases of Patients Treated in Countries With Limited Resources and Discussed by Experts of the International CML Foundation (iCMLf)-Case No. 2: Treatment-Free Remission After 9 Years of Imatinib Treatment Without Prior Achievement of Sustained Deep Molecular Response.","authors":"Mariana Bohns Michalowski, Meinolf Suttorp, Arlene Harriss-Buchan, Guiseppe Saglio, Nicola Evans, Nirmalya Roy Moulik","doi":"10.1155/crom/3942816","DOIUrl":"10.1155/crom/3942816","url":null,"abstract":"<p><p>Pediatric chronic myeloid leukemia (pCML) is a rare malignancy that nowadays is treated upfront with tyrosine kinase inhibitors (TKIs). As demonstrated in adult CML patients, achieving deep molecular response (DMR) and maintaining this status over 2 years results in the opportunity to discontinue TKI therapy. Following cessation, this treatment-free remission (TFR) status is successfully achieved by approximately 50% of the patients, while the other half experience molecular relapse within ≤ 6 months, requiring a TKI restart. As pCML accounts for only 2%-3% of all childhood leukemias, experience and familiarity with this disease, especially with stopping attempts, are still very limited. Small pCML cohorts enrolled in stopping TKI trials, with strict criteria applied for both depth and maintenance of DMR, have demonstrated the achievable TFR success rates seem comparable to adults. However, recommendations for considering TFR in pCML have yet to be defined. We report on a 9-year-old Brazilian boy diagnosed with CML in a chronic phase. He was treated with imatinib and achieved a molecular response (BCR::ABL1 transcript rate < 0.1%) at Month 12. Not achieving DMR, he responded well, but not optimally, to TKI therapy. Contrary to existing guidelines on TKI cessation in adults, after 9 years, imatinib was stopped. With a follow-up of 24 months, the patient is in TFR and now maintains DMR successfully. With the support of the International CML Foundation (iCMLf), which aims to improve outcomes for CML patients globally, this rare case from Brazil is discussed from the perspective of a pediatric hemato-oncologist from a high-income country, a pediatric hemato-oncologist from a low- and middle-income country, an adult CML hematologist, and the treating physician. Sharing cases of pCML in LMICs and highlighting the resources offered by the iCMLf, particularly the Knowledge Center (available online), will hopefully improve the expertise on pCML treatment worldwide.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2025 ","pages":"3942816"},"PeriodicalIF":0.6,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11952922/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Importance of Next-Generation Sequencing in Identifying Immunohistochemically Ambiguous Pediatric Sarcomas.","authors":"Chong Bin He, Dan Pham, Rachel S Kronenfeld, Andrew Rosenberg, Jessica Ardente, Aditi Dhir","doi":"10.1155/crom/9926653","DOIUrl":"10.1155/crom/9926653","url":null,"abstract":"<p><p>Bone and soft-tissue sarcomas encompass over 70 histologic subtypes, posing diagnostic challenges due to overlapping characteristics. Molecular analyses, such as fluorescence in situ hybridization (FISH) and reverse transcription polymerase chain reaction (RT-PCR), aid in identifying specific genomic alterations but are often limited, particularly when prior histological findings are inconclusive. Next-generation sequencing (NGS) offers high-throughput testing via a targeted sequencing panel, addressing these limitations. This case series highlights the utility of NGS in diagnosing two pediatric patients with immunobiologically ambiguous Ewing sarcoma (ES) and clear cell sarcoma (CCS), emphasizing its role as a powerful tool in solid tumor diagnosis.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2025 ","pages":"9926653"},"PeriodicalIF":0.6,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11925606/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143669211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synchronous Primary Malignancies: Incidental Detection of Ascending Colon Adenocarcinoma During Staging of Invasive Ductal Carcinoma of the Breast.","authors":"Salif Balde, Ulrich Igor Mbessoh Kengne, Jaafar Ibn Abou Talib Thiam, Joël Gabin Konlack Mekontso, Sokhna Diop Niang, Amacoumba Fall, Mamadou Ndiaye, Gorgui Sarr, Etienne Tossou Zoure, Mamadou Sow, Sidy Ka","doi":"10.1155/crom/7164628","DOIUrl":"https://doi.org/10.1155/crom/7164628","url":null,"abstract":"<p><p>Multiple primary malignant neoplasms (MPMNs) are defined as two or more distinct tumors in the same individual. Synchronous breast and colon cancers are infrequent and present management challenges due to the lack of standardized guidelines. We report a 73-year-old woman presenting with a right breast mass, subsequently diagnosed as Grade 2 invasive ductal carcinoma. Staging CT incidentally revealed right colon wall thickening, and colonoscopy with biopsy confirmed moderately differentiated invasive adenocarcinoma. Following neoadjuvant chemotherapy, she underwent simultaneous radical mastectomy with axillary lymph node dissection and right hemicolectomy. Postoperative recovery was uneventful. Adjuvant chemoradiation was administered per multidisciplinary team (MDT) recommendation. Synchronous breast and colon cancers pose unique diagnostic and treatment planning challenges. MDT collaboration is crucial for personalized treatment strategies and optimized outcomes in these complex cases.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2025 ","pages":"7164628"},"PeriodicalIF":0.6,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11991772/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune Checkpoint Inhibitor-Mediated Aseptic Meningitis and Hypophysitis.","authors":"Pavel Bleik, Panisara Fangsaard, Nataliya Yuklyaeva","doi":"10.1155/crom/3517328","DOIUrl":"https://doi.org/10.1155/crom/3517328","url":null,"abstract":"<p><p>Immune checkpoint inhibitors have revolutionized cancer treatment, yet their use is associated with unique and sometimes unpredictable immune-related adverse events. We present a case of a 67-year-old female with renal cell cancer treated with ipilimumab and nivolumab who developed aseptic meningitis and hypophysitis. This case highlights the challenges in managing immune-related adverse events and underscores the need for vigilance in monitoring patients receiving ICIs.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2025 ","pages":"3517328"},"PeriodicalIF":0.6,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11991839/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143985342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Remarkable Antitumor Effects and Serious Multiple Immune-Related Adverse Events in Malignant Pleural Mesothelioma: Two Case Reports.","authors":"Koharu Harada, Hidehiro Irie, Akifumi Mitsuishi, Takahiro Fukui, Nao Takada, Ryosuke Nagaoka, Yohei Funatsu, Hidefumi Koh","doi":"10.1155/crom/8768823","DOIUrl":"https://doi.org/10.1155/crom/8768823","url":null,"abstract":"<p><p>We describe two patients who experienced serious multiple immune-related adverse events (irAEs), treatment interruption, and steroid administration. Despite these challenges, they achieved a remarkable antitumor effect beyond the expected. Various carcinomas demonstrated a possible correlation between the antitumor effect of immune checkpoint inhibitors and the intensity of irAEs, but few studies report on malignant pleural mesothelioma (MPM). Our two cases exhibited much stronger irAEs than usual. These two cases still demonstrated a complete response (CR) or near CR partial response, indicating a correlation between irAEs and the antitumor effect in MPM.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2025 ","pages":"8768823"},"PeriodicalIF":0.6,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11991814/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143966668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intraoperative Cortical Sensorimotor Mapping During Glioma Resection Monitored With Drum Playing During Awake Craniotomy: A Case Report.","authors":"Priscella Asman, Israt Tasnim, Matthew Muir, Mathew Hall, Kyle Noll, Sarah Prinsloo, Giuseppe Pellizzer, Shreyas Bhavsar, Sudhakar Tummala, Nuri Ince, Sujit Prabhu","doi":"10.1155/crom/4625899","DOIUrl":"10.1155/crom/4625899","url":null,"abstract":"<p><p><b>Background:</b> Tumors infiltrating the precentral gyrus remain a unique operative challenge. In this study, we explored a novel approach for awake craniotomy involving a patient playing a drum pad during resection of low-grade glioma, with the use of preoperative navigated transcranial magnetic stimulation (nTMS)-generated diffusion tensor imaging (DTI) and high-density real-time electrocorticography (ECoG). <b>Observation:</b> A 36-year-old left-handed male with a low-grade glioma in the left hemisphere hand knob region had a grand mal seizure. We combined preoperative nTMS-DTI with intraoperative passive functional mapping using high-density real-time ECoG. During an awake craniotomy, the patient played a drum pad while we assessed somatosensory-evoked potentials (SSEPs) using a 64-channel ECoG grid. This confirmed the absence of motor-evoked potentials (MEPs) over the tumor area, consistent with nTMS findings. Continuous monitoring of the patient's drum pad performance during the resection allowed for a gross total resection (GTR) of the tumor. Following the resection, he experienced some weakness in the intrinsic muscles of his right hand, which returned to full normal function at 6 months. At the end of 1 year, he remained seizure-free. <b>Conclusion:</b> A multimodal mapping strategy combined with awake monitoring of drum playing enabled preservation of function while achieving GTR in a patient with a motor-eloquent glioma.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2025 ","pages":"4625899"},"PeriodicalIF":0.6,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11879599/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}